Resolve Therapeutics   Report issue

For profit Phase 2
Founded: Kirkland WA United States (2010)

Organization Overview

First Clinical Trial
2014
NCT02194400
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Resolve Therapeutics | Resolve Therapeutics LLC

Active Ingredients

Drugs in Phase 2 Trials (2)

rslv-132 (4 trials)

sodium chloride (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lupus Erythematosus, Systemic (Phase 2)

Sjogren's Syndrome (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 2